Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease
Clin Investig Arterioscler. 2017 Jul-Aug;29(4):185-200.
doi: 10.1016/j.arteri.2016.06.002.
Epub 2016 Sep 28.
[Article in
English,
Spanish]
Authors
Ángel Brea
1
, Xavier Pintó
2
, Juan F Ascaso
3
, Mariano Blasco
4
, Ángel Díaz
5
, Pedro González-Santos
6
, Antonio Hernández-Mijares
7
, Teresa Mantilla
8
, Jesús Millán
9
, Juan Pedro-Botet
10
; Grupo de trabajo sobre Dislipemia Aterogénica, Sociedad Española de Arteriosclerosis
Affiliations
- 1 Unidad de Lípidos, Servicio de Medicina Interna, Hospital San Pedro, Logroño, España. Electronic address: abrea@riojasalud.es.
- 2 Unidad de Lípidos y Riesgo Vascular, Servicio de Medicina Interna, Hospital Universitario de Bellvitge, Idibell, CiberObn, L'Hospitalet de Llobregat, Barcelona, España.
- 3 Servicio de Endocrinología, Hospital Clínico, Valencia, España.
- 4 Área Sanitaria de Delicias, Atención Primaria, Zaragoza, España.
- 5 Centro de Salud de Bembibre, Bembibre, León, España.
- 6 Departamento de Medicina, Universidad de Málaga, Málaga, España.
- 7 Servicio de Endocrinología, Hospital Universitario Dr. Peset, Universitat de València, Valencia, España.
- 8 Centro de Salud de Prosperidad, Atención Primaria, Madrid, España.
- 9 Unidad de Lípidos, Servicio de Medicina Interna, Hospital General Universitario Gregorio Marañón, Universidad Complutense, Madrid, España.
- 10 Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
Abstract
Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influence on cardiovascular disease and drugs used in the control of cardiovascular risk factors showing a beneficial effect on the liver disease will be reviewed.
Keywords:
Arteriosclerosis; Cardiovascular diseases; Cardiovascular risk; Enfermedad del hígado graso no alcohólica; Enfermedades cardiovasculares; Esteatohepatitis no alcohólica; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Riesgo cardiovascular; Tratamiento; Treatment.
Copyright © 2016 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Animals
-
Atherosclerosis / etiology*
-
Atherosclerosis / prevention & control
-
Cardiovascular Diseases / etiology*
-
Cardiovascular Diseases / prevention & control
-
Disease Progression
-
Humans
-
Non-alcoholic Fatty Liver Disease / complications*
-
Non-alcoholic Fatty Liver Disease / therapy
-
Risk Factors